Extremity soft tissue sarcoma: controversial management issues.
Unlike common malignancies, such as breast and colorectal carcinoma, where treatment modalities can be investigated with large prospective randomized trials, such an endeavor has been hampered with soft tissue sarcomas (STS) due to its rarity. In absence of such randomized clinical trials, controversy exists with regards to numerous clinically relevant questions and clinicians are left with single institutional experiences gathered either in a retrospective or prospective fashion. Some of these frequently encountered issues in the management of STS include (1) whether poorly executed biopsies affect outcome? (2) Do all unplanned excisions require re-excisions? (3) Is MRI a superior imaging modality? (4) Whether radiation should be provided pre- or post-operatively? (5) Does extent of surgical margin influence local control? (6) Is adjuvant radiation therapy necessary for stage IIB STS? (7) Does adjuvant chemotherapy influence local control? (8) Does local recurrence influence survival? We will address these topics in this review.
Khatri
Vijay P
VP
Division of Surgical Oncology, University of California, Davis, 4501 X Street, Suite 3010, Sacramento, CA 95817, USA.
Goodnight
James E
JE
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D017024:Chemotherapy, Adjuvant; D005121:Extremities / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012509:Sarcoma / Q000175:diagnosis* / Q000628:therapy*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents